Galera Therapeutics (GRTX)
(Delayed Data from OTC)
$0.05 USD
0.00 (-7.97%)
Updated Nov 6, 2024 03:09 PM ET
NA Value
NA Growth NA Momentum NA VGMGalera Therapeutics, Inc. (GRTX) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$N/A | $N/A | $N/A | N/A% |
Price Target
Galera Therapeutics, Inc. does not have any price target set by analysts.
Analyst Price Targets ()
Broker Rating
Galera Therapeutics, Inc. does not currently have any recommendation from brokerage firms.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | NA | NA | NA | NA | NA |
Buy | NA | NA | NA | NA | NA |
Hold | NA | NA | NA | NA | NA |
Sell | NA | NA | NA | NA | NA |
Strong Sell | NA | NA | NA | NA | NA |
ABR | NA | NA | NA | NA | NA |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
Not Identified | Not Identified | Not Identified | Not Identified | Not Identified |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | NA |
ABR (Last week) | NA |
# of Recs in ABR | NA |
Average Target Price | NA |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 95 of 252 |
Current Quarter EPS Est: | NA |